No More Federal Funding For Medical Marijuana Raids

No More Federal Funding For Medical Marijuana Raids

The war on drugs unfolded in the United States decades ago, but medical marijuana dispensaries are now being protected due to provisions in a recent federal spending bill.

The bill specifies that the Department of Justice is not allowed to use any part of their agency’s budget to pursue action against state-legal medical marijuana operations. Many businesses in states that legally allow marijuana for medical use have been raided for not complying with federal laws, even when they do comply with state laws. Once the spending bill goes into effect, these raids will no longer be permitted.

The bill was introduced by House Representatives Sam Farr and Dana Rohrabacher. Farr commented to the Huffington Post that this bill will ensure that federal tax dollars are used to prosecute criminals rather than restrict a patient’s legal use of marijuana. Reports estimate that almost $80 million per year has been spent to fight medical marijuana dispensaries during Obama’s administration. Farr also stated that more work needs to be done to align federal and state policies.

The new law means that medical marijuana dispensaries in 23 states will be protected from prosecution. Eleven states have also legalized the use of cannabidiol (CBD) oils, and this will also be protected. Cannabidiol is the marijuana cannabinoid known to be effective in the treatment of epilepsy. While state laws have permitted the use of marijuana for medical purposes, patients and their caregivers have repeatedly been arrested by the DEA for breaking federal drug laws. Marijuana remains listed as a Schedule I drug under the Controlled Substances Act, designating the plant as having zero recognized medicinal uses in the United States. Heroin and LSD are also Schedule I substances.

Americans for Safe Access released a statement praising the measure and noting that it will end the arrest and criminal conviction of patients using marijuana to ease medical conditions. Patients’ rights advocates are hopeful that the bill will lead to the end of civil asset forfeiture cases for patients as well.

Industrial hemp production is legalized in 18 states and will also be protected from prosecution under the regulations in the bill. Cannabis sativa is both marijuana and hemp. The difference is that hemp contains minimal amounts of the psychoactive cannabinoid THC. This number is less than 1.5 percent in hemp.

Research into hemp production is ongoing, and more than 12 states have introduced pieces of legislation to investigate hemp production or move forward with legalization of the process. For example, the DEA has permitted the state of Kentucky to begin a research program.

photo credit: Coleen Danger

FDA Approves Study for Cannabis Oil as Seizure Treatment

FDA Approves Study for Cannabis Oil as Seizure Treatment

The number of clinical studies that have been conducted on the use of cannabis oil in the treatment of different forms of epilepsy and other seizure disorders far under-represents the public want and need for such research. Parents of children suffering from such conditions in the United States, South America and the rest of the world have even rallied to draw attention to this crime against humanity. Being granted cannabis research permission is the United States is nearly impossible due to the current classification of marijuana as a Schedule I drug under the Controlled Substances Act. Until the federal government removes cannabis from this classification all together, like alcohol, more people, including children, will continue to suffer.

Last year, a coalition of parents with children suffering from different forms of epilepsy and seizure disorders was able to convince legislators in Alabama to approve a bill allowing such research. The study is to be conducted at the University of Alabama at Birmingham, and now, the Food and Drug Administration is officially approving the study.

Permission for this research has been granted to the UAB Neurology department, and reportedly aims to test the effectiveness of the marijuana cannabinoid, known as cannabidiol (CBD), as a treatment for seizure disorders. This study will be different than others conducted because there will be no placebo group. All participants will receive the cannabidiol rich extract during clinical trials. However, there is a catch. A university representative told ABC 3340 that the FDA approved the study with a few alterations. These modifications are expected to be discussed by a review board in January 2015, and hopefully the study will be able to begin soon thereafter.


photo credit: dr-bonni.bitnamiapp

Subscribe To Our Newsletter

Join our mailing list to receive the latest news and updates from our team.

You have Successfully Subscribed!

[data-image-id='gourmet_bg']
[data-image-id='gourmet_bg']
[data-image-id='gourmet_bg']
[data-image-id='gourmet_bg']
[data-image-id='gourmet_bg']
[data-image-id='gourmet_bg']
[data-image-id='gourmet']
[data-image-id='gourmet']
[data-image-id='gourmet']
[data-image-id='gourmet']
[data-image-id='gourmet']
[data-image-id='gourmet']
[data-image-id='gourmet']
[data-image-id='gourmet']
[data-image-id='gourmet']
[data-image-id='gourmet']